You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Targeted therapy is one of the most burgeoning areas of development in cancer research. Increasing knowledge in tumor formation and growth at the molecular level has generated a broad array of therapeutic options, including signal transduction inhibition, anti-angiogenic and anti-vascular agents, cell cycle inhibitors, telomerase and telomere inter
This 2006 book examines the interaction of economics and the delivery of cancer care in the global context. It analyses the causes of tension between those paying for care, those providing the care and those marketing drugs and devices. The concept and requirement for rationing is examined in different economic environments. As cancer increases in incidence and prevalence, the economics of providing care becomes a more important subject than ever before. Written by a leading health economist and oncologist, this was the first comprehensive book on the economics of cancer care continues to be of interest to health professionals and policy makers alike.
- Discusses the latest drug treatments in the field - Gleevec arranged a bulk sale for this title - Written by leaders in the industry
TI has received honoraria from Eisai as a consultant and grants or funding to his institution from Novartis. TI participated in congress for which travel and accommodations were paid by Ipsen, Pharmamar, and Novartis.
Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a...
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
In this issue of Surgical Oncology Clinics, guest editors Drs. Chandrajit P. Raut and Alessandro Gronchi bring their considerable expertise to the topic of Sarcoma. Top experts in the field provide articles on management of common types of sarcoma, as well as drug trials, WHO updates, and clinical trials. - Contains 15 relevant, practice-oriented topics including relevant trials update in sarcomas and GIST: what surgeons should know; management of retroperitoneal/mesenteric liposarcoma; management of solitary fibrous tumors; management of skin sarcomas (AS, LMS, DFSP, AFX); management of leiomyosarcoma; and more. - Provides in-depth clinical reviews on sarcoma, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Effective care of the cancer patient increasingly involves systemic treatment, and as the range of available therapeutic agents continues to expand, the medical oncologist must be fully aware of the rationale for choosing specific drugs and combinations. Textbook of Medical Oncology, 4th edition, is written by a highly acclaimed list of internation
Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments. These therapies notably include: Targeted agents of immune checkpoints Signal-transduction inhibitors Antiangiogenic agents Vascular-disrupting agents Apoptosis modulators Stem cell inhibitors Tumor profiling for drug development The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world.
For more than 30 years, Skeel’s Handbook of Cancer Therapy (formerly Handbook of Cancer Chemotherapy) has been the resource of choice for current, reliable information on cancer treatment for most adults. The 9th Edition reflects recent significant advances in the systemic treatment of cancer, including innovations in immunotherapy, oncology genomics, and molecular targeted therapy. An invaluable reference for all levels of physicians, nurses, and allied health professionals who provide care to cancer patients, this bestselling guide combines the most current rationale and the details necessary to safely administer pharmacologic therapy, offering a balanced synthesis between science and clinical practice.